After search, choose a molecule or a kind of categories listed in the left to narrow down your filter. If you have any problems, please contact us!
Text Size:AAA

CD166 / ALCAM Antibody (PE), Mouse MAb

DatasheetSpecific ReferencesReviewsRelated ProductsProtocols
Human CD166/ALCAM Antibody Product Information
Immunogen:Recombinant Human CD166 / ALCAM protein (Catalog#10045-H08H)
Clone ID:03
Ig Type:Mouse IgG1
Concentration:10 μl/Test, 0.1 mg/ml
Formulation:Aqueous solution containing 0.5% BSA and 0.09% sodium azide
Preparation:This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human CD166 / ALCAM (rh CD166 / ALCAM; Catalog#10045-H08H; NP_001618.2; Met 1-Ala 526) and conjugated with PE under optimum conditions, the unreacted PE was removed.
Human CD166/ALCAM Antibody Usage Guide
Specificity:Human CD166 / ALCAM
No cross-reactivity in ELISA with
Human BCAM
Human CD146
Human CD171
Human EpCAM
Human cell lysate (293 cell line)
Storage:This antibody is stable for 12 months from date of receipt when stored at 2℃-8℃. Protected from prolonged exposure to light. Do not freeze !
Sodium azide is toxic to cells and should be disposed of properly. Flush with large volumes of water during disposal.
Human CD166/ALCAM Antibody FC Application Image
[Click to enlarge image]
Profile of anti-ALCAM (CD166) reactivity on Jurkat cells analyzed by flow cytometry.
CD166 / ALCAM Antibody (PE), Mouse MAb, Flow cytometric
Other CD166/ALCAM Antibody Products
CD166/ALCAM Background

Activated leukocyte cell adhesion molecule (ALCAM)/Cluster of differentiation (CD166) is a type I transmembrane cell adhesion molecule belonging to the Ig superfamily and a ligand for CD6 that is expressed on T lymphocytes. The extracellular domain of ALCAM contains five Ig-like domains (three Ig-like C2-type domains and two Ig-like V-type domains), of which the amino-terminal V1 domain is essential for ligand binding and ALCAM-mediated cell aggregation. ALCAM mediates both heterophilic (ALCAM-CD6) and homophilic (ALCAM-ALCAM) cell-cell interactions. ALCAM/CD6 interaction plays a role in T cell development and T cell regulation, as well as in the binding of T- and B-cells to activated leukocytes. Recently, homophilic (ALCAM-ALCAM) adhesion was shown to play important roles in tight cell-to-cell interaction and regulation of stem cell differentiation. While expressed in a wide variety of tissues, ALCAM is usually restricted to subsets of cells involved in dynamic growth and/or migration, including neural development, branching organ development, hematopoiesis, immune response and tumor progression. And CD166 is regarded as a potential novel breast cancer indicator and therapeutic target.

Human CD166/ALCAM References
  • Swart GW. (2002) Activated leukocyte cell adhesion molecule (CD166/ALCAM): developmental and mechanistic aspects of cell clustering and cell migration. Eur J Cell Biol. 81(6): 313-21.
  • Fujiwara H, et al. (2003) Human blastocysts and endometrial epithelial cells express activated leukocyte cell adhesion molecule (ALCAM/CD166). J Clin Endocrinol Metab. 88(7): 3437-43.
  • Jezierska A, et al. (2006) ALCAM/CD166 protects breast cancer cells against apoptosis and autophagy. Med Sci Monit. 12(8): BR263-73.
  • Kahlert C, et al. (2009) Increased expression of ALCAM/CD166 in pancreatic cancer is an independent prognostic marker for poor survival and early tumour relapse. Br J Cancer. 101(3): 457-64.
  • Product nameProduct name